Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?
Authors:
- 3 June 2015
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Abstract
Trastuzumab has significantly improved the median survival of patients with HER2-positive breast cancer. In metastatic disease, maintenance trastuzumab is usually given after tumour response has been achieved with the combination of chemotherapy and trastuzumab, with the aim of prolonging time to disease progression. We report a case where a durable complete response (CR) was achieved without maintenance trastuzumab. In the absence of consensus guidelines, it is difficult to recommend which HER2-positive patients with metastatic breast cancer after CR will benefit from withdrawing maintenance trastuzumab therapy and when this could be considered.Keywords
This publication has 24 references indexed in Scilit:
- Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancerAnnals of Oncology, 2012
- 5000 ORAL Long-term Outcome of HER2-positive (HER2+) Metastatic Breast Cancer (MBC) Patients (pts) Achieving Durable Complete Remission (DCR) After Trastuzumab (T)-containing Chemotherapy (CT)European Journal of Cancer, 2011
- Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case reportJournal of Medical Case Reports, 2010
- Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast CancerThe Oncologist, 2008
- Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survivalAnnals of Oncology, 2008
- Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 AmplificationClinical Cancer Research, 2007
- HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based TherapyThe Oncologist, 2006
- First line chemotherapy of metastatic breast cancerAnnals of Oncology, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001